Axonis Therapeutics
Novel small molecule therapeutics for axon regeneration and tissue reactivation.
Axonis Therapeutics is developing medicines for neuron restoration and neuromodulation. Therapies are aimed at enabling neural tissue to resist degeneration, restore healthy electrical balance, and promote neural regeneration. Successful pre-clinical POC studies have been completed, and a clinical trial is planned for 2024 / 25.
Technology
How they’re delivering breakthroughs
- Next generation KCC2 potentiator to restore healthy electrical balance
- KCC2 potentiation to reactivate spare neuronal tissue after injury
- Small molecule therapeutics to silence degenerative signals
Impact
How they’re making a difference
- Clinical trial planned for end of 2024 / 2025
- Broad disease areas including traumatic injuries to the nervous system, neurodegenerative diseases, epilepsy and pain
